Х.Ариунаа
Loading...
Товч нэр
Х.Ариунаа
Бүтэн нэр
Хасбазар Ариунаа
Латин нэр
Khasbazar Ariunaa
Албан тушаал
Ахлах багш
Харьяалал
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison of Adverse Events Between Selective Internal Radiation Therapy Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma in Mongolia: A Subgroup Analysis of SIRveNIB Study(Mongolian National University of Medical Sciences, 2017-11-25); ; ;Bolormaa Yalhgar ;Tuyatsetseg AltankhuyagObjective: This study compared the adverse events associated with selective internal radiation therapy to sorafenib in the treatment of patients with locally advanced hepatocellular carcinoma (HCC). Methods: From March 2011 to June 2106, the National Cancer Center of Mongolia recruited 39 patients from Mongolia (19 received sorafenib and 20 received SIRT in Singapore) with advanced hepatocellular carcinoma who had not received surgical therapy into a multicenter study involving a total of 360 patients at 27 sites in 11 Asia-Pacific countries. The study was a phase III randomized-controlled clinical trial comparing sorafenib or SIRT. Results: Adverse events for patients receiving sorafenib were predominantly grade 1 or 2 in gastrointestinal, constitutional and dermatologic in nature. The most frequently reported drug-related adverse events in patients treated with sorafenib were hypertension, hand-foot skin reaction, diarrhea, alopecia, fatigue. Common procedure-related adverse events were usually mild (grade 1/2) and included nausea and vomiting (27.7% all grades) and abdominal pain (22.1% all grades), with very few grades 3 or greater adverse events. Conclusion: In our analysis of 39 patients, we were unable to detect a statistically significant difference in adverse effects between sorafenib and SIRT treatment groups, likely because there were insufficient number patients in our study. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Mongolian Patients with Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the SIRveNIB Study(Mongolian National University of Medical Sciences, 2019-09-25); ;Sanduijav Rubjir ;Baasanjav NachinObjective: The purpose of this study was to compare the efficacy and safety of selective internal radiation therapy and sorafenib on advanced hepatocellular carcinoma. Methods: The National Cancer Center of Mongolia was one of the Asia-Pacific Liver Cancer Research Team sites, and we recruited patients into the study. Patients were randomly assigned 1:1 stratified and to receive either SIRT or sorafenib 800 mg/d orally. Outcome measures were physical examination, functional assessment, CBC, liver function test, AFP results, and CT scan every 4, 8 and, 12 weeks after treatment initiation. Results: Between March 2011 and June 2016, 39 patients were enrolled in the study. Twenty patients were treated with SIRT, and 19 patients were treated with sorafenib. Median OS and PFS rates were no different in sorafenib arm patients than in SIRT arm (15.56 vs. 9.17; HR 0.95, 95% CI 0.46, p = .889) and (8.51 months vs. 5.85 months; HR,1.07; CI, 0.53-2.16, p = .842). But, tumor response was greater in SIRT than sorafenib treatment (68.8% vs 62.5%, p = .033). Two (10%) patients had a complete response, 2 (10%) patients had a partial response, and 7 (43.8%) patients had a stable response. A total of 165 treatment-emergent adverse events were reported (SIRT 66 vs. sorafenib 99). Significantly fewer patients in the SIRT than sorafenib group had grade ≥3 adverse events (83 vs. 115, p = .0964). Conclusion: In patients with locally advanced hepatocellular carcinoma, overall survival did not differ significantly between SIRT and sorafenib. But SIRT significantly increased tumor response and reduced the incidence of adverse events compared with sorafenib.
